These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. Gatto F; Barbieri F; Arvigo M; Thellung S; Amarù J; Albertelli M; Ferone D; Florio T Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412614 [TBL] [Abstract][Full Text] [Related]
7. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624 [TBL] [Abstract][Full Text] [Related]
8. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro. Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235 [TBL] [Abstract][Full Text] [Related]
9. [New medical treatments in pituitary adenomas]. Drutel A; Caron P; Archambeaud F Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854 [TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Schaer JC; Waser B; Mengod G; Reubi JC Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751 [TBL] [Abstract][Full Text] [Related]